Cue Biopharma 2025 Q2 Earnings Narrowed Losses with Modest Revenue Growth

Cue Biopharma (CUE) reported its fiscal 2025 Q2 earnings on August 12, 2025. The company posted a modest revenue increase and reduced losses, although continued net losses underscore long-term financial challenges. Investors were left with mixed signals as the post-earnings trading strategy underperformed significantly.

Cue Biopharma’s total revenue rose 11.1% year-over-year to $2.95 million in Q2 2025, driven entirely by collaboration revenue, which accounted for the full $2.95 million in total revenue. This marks a modest improvement from the $2.66 million reported in the same period a year ago.

The company narrowed its net loss to $8.48 million in Q2 2025, a 16.6% reduction from the $10.17 million loss in Q2 2024. On a per-share basis, the loss improved to $0.09 from $0.20, representing a 55.0% improvement. Despite these reductions, Cue Biopharma has now posted losses for seven consecutive years in this quarterly period, highlighting persistent financial difficulties. The earnings reflect progress but fall short of suggesting long-term profitability.

The stock price of Cue Biopharma experienced a mixed post-earnings performance. Over the latest trading day, the stock fell by 2.05%, while the weekly decline reached 5.74%. However, it posted a 3.13% gain month-to-date, showing some resilience.

The post-earnings trading strategy—buying shares on the report date following a revenue increase and holding for 30 days—underperformed severely. The strategy returned -65.35%, significantly lagging the benchmark by 133.11%. The Sharpe ratio of -0.48 underscored the high risk involved, while a maximum drawdown of 0% suggested the strategy avoided deeper losses but still resulted in substantial value erosion.

Daniel Passeri, CEO of Cue Biopharma, emphasized the company’s scientific and strategic progress, including encouraging Phase 1b clinical data for CUE-101 and key developments in autoimmune programs. He also highlighted collaboration opportunities, such as the strategic partnership with Boehringer Ingelheim for CUE-501, and regulatory feedback on CUE-401. The tone was forward-looking and constructive, despite ongoing financial challenges.

Cue Biopharma did not provide any forward-looking financial guidance or operational projections for future periods. Management refrained from making statements such as “we expect” or “we anticipate,” leaving investors without clear expectations for near-term performance or milestones.

Additional News
In the three weeks surrounding Cue Biopharma’s earnings release, several noteworthy non-earnings related events occurred. In Nigeria, Anambra State Governor Charles Soludo announced his support for President Bola Tinubu in the 2027 elections, citing a 22-year friendship and economic reforms. Meanwhile, the Nigerian Correctional Service revealed a mental health crisis among inmates, with over 8,244 individuals suffering from mental illness. Schneider Electric was named the World’s Most Sustainable Company for the second year, underscoring global sustainability efforts. In academia, Ebonyi State’s new university fee hikes sparked backlash from parents. Lastly, a former Sokoto State Governor was granted bail by the Economic and Financial Crimes Commission after being questioned over alleged fraudulent transactions.